CAPS
Capstone Holding Corp. Common Stock
stockNASDAQ
capstone therapeutics (otcqb: caps) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. capstone holds an fda orphan drug designation for its lead molecule, aem-28, for homozygous familial hypercholesterolemia (hofh) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.13 | 2026-10-12 | +1893.25% | -3.522 |
| 1M | 0.18 | 2026-09-18 | +1414.82% | -0.329 |
| 3M | 0.26 | 2026-07-20 | +936.68% | -0.185 |
| 6M | 0.41 | 2026-04-20 | +549.32% | 1.017 |
| 1Y | 1.02 | 2025-10-20 | +160.49% | 0.670 |
| 2Y | 3.20 | 2024-10-16 | -16.97% | — |
| 5Y | 16.00 | 2021-10-12 | -83.39% | 1.086 |
Capstone Holding Corp. Common Stock (NASDAQ:CAPS) stock price today is $2.66, and today's volume is 120,998. CAPS is up 2954.023% today. The 30 day average volume is 8.82M. CAPS market cap is $2.34M with 879,470 shares outstanding.